U.S. Advanced Wound Care Market by Product (Infection Management, Exudate Management, Active Wound Care, Therapy Devices), Application (Chronic Wounds and Acute Wounds), and End User (Hospitals and Community Centers): Opportunity Analysis and Industry Forecast, 2020–2027
The U.S. advanced wound care market was valued at $3.35 billion in 2019 and is expected to reach $4.97 billion by 2027, registering a CAGR of 9.9% from 2020 to 2027.
Advanced wound care products offer relief to patients suffering from chronic wounds, which takes more time to heal and are expensive to treat. Wound healing process can be facilitated in two different ways, which include traditional wound care (TWC) and advanced wound care (AWC). Advanced wound care products enable faster healing, owing to their efficiency & effectiveness in managing wounds.
Significant increase in prevalence of chronic diseases such as diabetes & obesity, rise in geriatric population, problems associated with traditional wound healing methods, and surge in adoption of evidence-based treatments such as silver dressings, hyperbaric oxygen, electrotherapy, and ultrasound for chronic wounds are the key factors that fuel growth of the U.S. advanced wound care market. Moreover, rise in awareness programs for advanced wound care treatment & management, attempts to reduce duration of the hospital stay to lower healthcare expenses, and rise in inclination toward wound care products that enhance therapeutic outcomes are other factors that contribute toward growth of the market.
The U.S. advanced wound care market is segmented into product, application, and end user. By product, the market is categorized into infection management, exudate management, active wound care, and therapy devices. The infection management is sub segmented into silver dressings, non-silver dressings, and collagens. The exudate management segment is further divided into hydrocolloid dressings, foam dressings, alginate dressings, and hydrogel dressings. The active wound care is subdivided into skin substitutes and growth factors. The skin substitute is further segmented into xenograft, allografts, and cell-based bioengineering. The therapy devices is further segmented into negative pressure wound therapy (NPWT), oxygen & hyperbaric oxygen equipment, electromagnetic therapy devices, and others. The applications covered in the study include chronic wounds and acute wounds. The chronic wounds segment is further segregated into pressure ulcers, diabetic foot ulcers, venous leg ulcers, and arterial ulcers. The acute wounds is further fragmented into burns & trauma, and surgical wounds. Depending on end user, the market is classified into hospitals and community health service centers.
KEY BENEFITS FOR STAKEHOLDERS
Advanced wound care products offer relief to patients suffering from chronic wounds, which takes more time to heal and are expensive to treat. Wound healing process can be facilitated in two different ways, which include traditional wound care (TWC) and advanced wound care (AWC). Advanced wound care products enable faster healing, owing to their efficiency & effectiveness in managing wounds.
Significant increase in prevalence of chronic diseases such as diabetes & obesity, rise in geriatric population, problems associated with traditional wound healing methods, and surge in adoption of evidence-based treatments such as silver dressings, hyperbaric oxygen, electrotherapy, and ultrasound for chronic wounds are the key factors that fuel growth of the U.S. advanced wound care market. Moreover, rise in awareness programs for advanced wound care treatment & management, attempts to reduce duration of the hospital stay to lower healthcare expenses, and rise in inclination toward wound care products that enhance therapeutic outcomes are other factors that contribute toward growth of the market.
The U.S. advanced wound care market is segmented into product, application, and end user. By product, the market is categorized into infection management, exudate management, active wound care, and therapy devices. The infection management is sub segmented into silver dressings, non-silver dressings, and collagens. The exudate management segment is further divided into hydrocolloid dressings, foam dressings, alginate dressings, and hydrogel dressings. The active wound care is subdivided into skin substitutes and growth factors. The skin substitute is further segmented into xenograft, allografts, and cell-based bioengineering. The therapy devices is further segmented into negative pressure wound therapy (NPWT), oxygen & hyperbaric oxygen equipment, electromagnetic therapy devices, and others. The applications covered in the study include chronic wounds and acute wounds. The chronic wounds segment is further segregated into pressure ulcers, diabetic foot ulcers, venous leg ulcers, and arterial ulcers. The acute wounds is further fragmented into burns & trauma, and surgical wounds. Depending on end user, the market is classified into hospitals and community health service centers.
KEY BENEFITS FOR STAKEHOLDERS
- This report provides a detailed quantitative analysis of the current market trends and future estimations from 2020 to 2027, which assists in identifying the prevailing market opportunities.
- An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate country-specific plans.
- A comprehensive analysis of the factors that drive and restrain the growth of the U.S. advanced wound care market is provided.
- By Product
- Infection Management
- Silver Wound Dressings
- Non-silver Dressings
- Collagen Dressings
- Exudate Management
- Hydrocolloids Dressings
- Foam Dressings
- Alginate Dressings
- Hydrogel Dressings
- Active Wound Care
- Skin Substitutes
- Xenograft
- Allografts
- Cell-based bioengineering
- Growth Factors
- Therapy Devices
- Negative Pressure Wound Therapy (NPWT)
- Oxygen and Hyperbaric Oxygen Equipment
- Electromagnetic Therapy Devices
- Others
- By Application
- Chronic Wounds
- Pressure Ulcers
- Diabetic Foot Ulcers
- Venous Leg Ulcers
- Arterial Ulcers
- Acute Wounds
- Burns & Trauma
- Surgical Wounds
- By End User
- Hospitals
- Community Health Service Centers
- 3M (Acelity Inc.)
- Adynxx, Inc.
- B Braun Melsungen AG
- Coloplast A/S
- ConvaTec Group Plc
- Essity AB (BSN Medical GmbH)
- Integra Lifesciences (Derma sciences)
- M?lnlycke Health Care AB
- Johnson & Johnson
- Medline Industries, Inc.
- Medtronic Plc.
- Organogenesis Holdings Inc.
- Smith & Nephew Plc.
- Paul Hartmann
- Human Biosciences Inc.
- Kinetic Concept, Inc.
- Mimedx Group
- Mpm Medical (RBC Life Sciences)
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key Benefits for Stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s five force analysis
3.4.Market share analysis
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Rise in geriatric population
3.5.1.2.Surge in incidences of diabetes, obesity, and chronic conditions
3.5.1.3.Changes in the healthcare system
3.5.2.Restraint
3.5.2.1.High cost of advanced wound care products
3.5.3.Opportunities
3.5.3.1.Technological advancements to deal with complex wounds
3.6.Impact analysis of COVID-19 on U.S. advanced wound care market
CHAPTER 4:ADVANCED WOUND CARE MARKET, BY PRODUCT
4.1.Overview
4.1.1.Market size and forecast
4.2.Infection management
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast
4.2.3.Market size and forecast, by type
4.2.4.Silver wound dressings
4.2.4.1.Market size and forecast
4.2.5.Non-silver dressings
4.2.5.1.Market size and forecast
4.2.6.Collagen dressings
4.2.6.1.Market size and forecast
4.3.Exudate management
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.3.3.Market size and forecast, by type
4.3.4.Hydrocolloid dressings
4.3.4.1.Market size and forecast
4.3.5.Foam dressings
4.3.5.1.Market size and forecast
4.3.6.Alginate dressings
4.3.6.1.Market size and forecast
4.3.7.Hydrogel dressings
4.3.7.1.Market size and forecast
4.4.Active wound care
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast
4.4.3.Market size and forecast, by type
4.4.4.Skin substitutes
4.4.4.1.Market size and forecast, by type
4.4.4.2.Xenograft
4.4.4.2.1.Market size and forecast
4.4.4.3.Allografts
4.4.4.3.1.Market size and forecast
4.4.4.4.Cell-based bioengineering
4.4.4.4.1.Market size and forecast
4.4.5.Growth factors
4.4.5.1.Market size and forecast
4.5.Therapy devices
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by type
4.5.3.Negative pressure wound therapy (NPWT)
4.5.3.1.Market size and forecast
4.5.4.Oxygen & hyperbaric oxygen equipment
4.5.4.1.Market size and forecast
4.5.5.Electromagnetic therapy devices
4.5.5.1.Market size and forecast
4.5.6.Others
4.5.6.1.Market size and forecast
CHAPTER 5:ADVANCED WOUND CARE MARKET, BY APPLICATION
5.1.Overview
5.1.1.Market size and forecast
5.2.Chronic wounds
5.2.1.Market size and forecast, by type
5.2.2.Pressure ulcers
5.2.2.1.Market size and forecast
5.2.3.Diabetic foot ulcers
5.2.3.1.Market size and forecast
5.2.4.Venous leg ulcers
5.2.4.1.Market size and forecast
5.2.5.Arterial ulcers
5.2.5.1.Market size and forecast
5.3.Acute wounds
5.3.1.Market size and forecast, by type
5.3.2.Burns & trauma
5.3.2.1.Market size and forecast
5.3.3.Surgical wounds
5.3.3.1.Market size and forecast
CHAPTER 6:ADVANCED WOUND CARE MARKET, BY END USER
6.1.Overview
6.1.1.Market size and forecast
6.2.Hospitals
6.2.1.Market size and forecast
6.3.Community health service centers
6.3.1.Market size and forecast
CHAPTER 7:COMPANY PROFILES
7.1.3M (ACELITY INC.)
7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance
7.1.6.Key strategic moves and developments
7.2.ADYNXX, INC.
7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product portfolio
7.2.5.Key strategic moves and developments
7.3.B BRAUN MELSUNGEN AG
7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance
7.4.COLOPLAST A/S
7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance
7.5.CONVATEC GROUP PLC.
7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance
7.6.ESSITY AB (BSN MEDICAL GMBH)
7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance
7.6.6.Key strategic moves and developments
7.7.INTEGRA LIFESCIENCES (DERMA SCIENCES)
7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Business performance
7.8.INVESTOR AB (M?LNLYCKE HEALTH CARE AB)
7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.9.JOHNSON & JOHNSON
7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance
7.10.MEDLINE INDUSTRIES, INC.
7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.11.MEDTRONIC PLC.
7.11.1.Company overview
7.11.2.Company snapshot
7.11.3.Operating business segments
7.11.4.Product portfolio
7.11.5.Business performance
7.12.ORGANOGENESIS HOLDINGS INC.
7.12.1.Company overview
7.12.2.Company snapshot
7.12.3.Operating business segments
7.12.4.Product portfolio
7.12.5.Business performance
7.13.SMITH & NEPHEW PLC.
7.13.1.Company overview
7.13.2.Company snapshot
7.13.3.Operating business segments
7.13.4.Product portfolio
7.13.5.Business performance
1.1.Report description
1.2.Key Benefits for Stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s five force analysis
3.4.Market share analysis
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Rise in geriatric population
3.5.1.2.Surge in incidences of diabetes, obesity, and chronic conditions
3.5.1.3.Changes in the healthcare system
3.5.2.Restraint
3.5.2.1.High cost of advanced wound care products
3.5.3.Opportunities
3.5.3.1.Technological advancements to deal with complex wounds
3.6.Impact analysis of COVID-19 on U.S. advanced wound care market
CHAPTER 4:ADVANCED WOUND CARE MARKET, BY PRODUCT
4.1.Overview
4.1.1.Market size and forecast
4.2.Infection management
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast
4.2.3.Market size and forecast, by type
4.2.4.Silver wound dressings
4.2.4.1.Market size and forecast
4.2.5.Non-silver dressings
4.2.5.1.Market size and forecast
4.2.6.Collagen dressings
4.2.6.1.Market size and forecast
4.3.Exudate management
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.3.3.Market size and forecast, by type
4.3.4.Hydrocolloid dressings
4.3.4.1.Market size and forecast
4.3.5.Foam dressings
4.3.5.1.Market size and forecast
4.3.6.Alginate dressings
4.3.6.1.Market size and forecast
4.3.7.Hydrogel dressings
4.3.7.1.Market size and forecast
4.4.Active wound care
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast
4.4.3.Market size and forecast, by type
4.4.4.Skin substitutes
4.4.4.1.Market size and forecast, by type
4.4.4.2.Xenograft
4.4.4.2.1.Market size and forecast
4.4.4.3.Allografts
4.4.4.3.1.Market size and forecast
4.4.4.4.Cell-based bioengineering
4.4.4.4.1.Market size and forecast
4.4.5.Growth factors
4.4.5.1.Market size and forecast
4.5.Therapy devices
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by type
4.5.3.Negative pressure wound therapy (NPWT)
4.5.3.1.Market size and forecast
4.5.4.Oxygen & hyperbaric oxygen equipment
4.5.4.1.Market size and forecast
4.5.5.Electromagnetic therapy devices
4.5.5.1.Market size and forecast
4.5.6.Others
4.5.6.1.Market size and forecast
CHAPTER 5:ADVANCED WOUND CARE MARKET, BY APPLICATION
5.1.Overview
5.1.1.Market size and forecast
5.2.Chronic wounds
5.2.1.Market size and forecast, by type
5.2.2.Pressure ulcers
5.2.2.1.Market size and forecast
5.2.3.Diabetic foot ulcers
5.2.3.1.Market size and forecast
5.2.4.Venous leg ulcers
5.2.4.1.Market size and forecast
5.2.5.Arterial ulcers
5.2.5.1.Market size and forecast
5.3.Acute wounds
5.3.1.Market size and forecast, by type
5.3.2.Burns & trauma
5.3.2.1.Market size and forecast
5.3.3.Surgical wounds
5.3.3.1.Market size and forecast
CHAPTER 6:ADVANCED WOUND CARE MARKET, BY END USER
6.1.Overview
6.1.1.Market size and forecast
6.2.Hospitals
6.2.1.Market size and forecast
6.3.Community health service centers
6.3.1.Market size and forecast
CHAPTER 7:COMPANY PROFILES
7.1.3M (ACELITY INC.)
7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance
7.1.6.Key strategic moves and developments
7.2.ADYNXX, INC.
7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product portfolio
7.2.5.Key strategic moves and developments
7.3.B BRAUN MELSUNGEN AG
7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance
7.4.COLOPLAST A/S
7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance
7.5.CONVATEC GROUP PLC.
7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance
7.6.ESSITY AB (BSN MEDICAL GMBH)
7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance
7.6.6.Key strategic moves and developments
7.7.INTEGRA LIFESCIENCES (DERMA SCIENCES)
7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Business performance
7.8.INVESTOR AB (M?LNLYCKE HEALTH CARE AB)
7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.9.JOHNSON & JOHNSON
7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance
7.10.MEDLINE INDUSTRIES, INC.
7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.11.MEDTRONIC PLC.
7.11.1.Company overview
7.11.2.Company snapshot
7.11.3.Operating business segments
7.11.4.Product portfolio
7.11.5.Business performance
7.12.ORGANOGENESIS HOLDINGS INC.
7.12.1.Company overview
7.12.2.Company snapshot
7.12.3.Operating business segments
7.12.4.Product portfolio
7.12.5.Business performance
7.13.SMITH & NEPHEW PLC.
7.13.1.Company overview
7.13.2.Company snapshot
7.13.3.Operating business segments
7.13.4.Product portfolio
7.13.5.Business performance
LIST OF TABLES
TABLE 01.U.S. INCIDENCES OF DIABETES, 2011 VS. 2030 (IN MILLION)
TABLE 02.U.S. ADVANCED WOUND CARE MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 03.INFECTION MANAGEMENT ADVANCED WOUND CARE MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 04.EXUDATE MANAGEMENT ADVANCED WOUND CARE MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 05.ACTIVE WOUND CARE MARKET ADVANCED WOUND CARE, BY TYPE, 2019–2027 ($MILLION)
TABLE 06.U.S. ADVANCED WOUND CARE FOR SKIN SUBSTITUTE, BY TYPE, 2019–2027 ($MILLION)
TABLE 07.THERAPY DEVICES ADVANCED WOUND CARE MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 08.U.S. ADVANCED WOUND CARE MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 09.U.S. ADVANCED WOUND CARE MARKET FOR CHRONIC WOUND, BY TYPE, 2019–2027 ($MILLION)
TABLE 10.PRESSURE ULCER-RELATED PRODUCTS AND MANUFACTURERS
TABLE 11.U.S. ADVANCED WOUND CARE MARKET FOR ACUTE WOUND, BY TYPE, 2019–2027 ($MILLION)
TABLE 12.U.S. ADVANCED WOUND CARE MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 13.3M: COMPANY SNAPSHOT
TABLE 14.3M: OPERATING SEGMENTS
TABLE 15.3M: PRODUCT PORTFOLIO
TABLE 16.ADYNXX: COMPANY SNAPSHOT
TABLE 17.ADYNXX: PRODUCT PORTFOLIO
TABLE 18.B BRAUN: COMPANY SNAPSHOT
TABLE 19.B BRAUN: OPERATING SEGMENTS
TABLE 20.B BRAUN: PRODUCT PORTFOLIO
TABLE 21.COLOPLAST: COMPANY SNAPSHOT
TABLE 22.COLOPLAST: OPERATING SEGMENTS
TABLE 23.COLOPLAST: PRODUCT PORTFOLIO
TABLE 24.CONVATEC: COMPANY SNAPSHOT
TABLE 25.CONVATEC: OPERATING SEGMENTS
TABLE 26.CONVATEC: PRODUCT PORTFOLIO
TABLE 27.ESSITY: COMPANY SNAPSHOT
TABLE 28.ESSITY: OPERATING SEGMENTS
TABLE 29.ESSITY: PRODUCT PORTFOLIO
TABLE 30.INTEGRA LIFESCIENCES: COMPANY SNAPSHOT
TABLE 31.INTEGRA LIFESCIENCES: OPERATING SEGMENTS
TABLE 32.INTEGRA LIFESCIENCES: PRODUCT PORTFOLIO
TABLE 33.INVESTOR: COMPANY SNAPSHOT
TABLE 34.INVESTOR: OPERATING SEGMENTS
TABLE 35.INVESTOR: PRODUCT PORTFOLIO
TABLE 36.J&J: COMPANY SNAPSHOT
TABLE 37.J&J: OPERATING SEGMENTS
TABLE 38.J&J: PRODUCT PORTFOLIO
TABLE 39.MEDLINE: COMPANY SNAPSHOT
TABLE 40.MEDLINE: OPERATING SEGMENTS
TABLE 41.MEDLINE: PRODUCT PORTFOLIO
TABLE 42.MEDTRONIC: COMPANY SNAPSHOT
TABLE 43.MEDTRONIC: OPERATING SEGMENTS
TABLE 44.MEDTRONIC: PRODUCT PORTFOLIO
TABLE 45.ORGANOGENESIS: COMPANY SNAPSHOT
TABLE 46.ORGANOGENESIS: OPERATING SEGMENTS
TABLE 47.ORGANOGENESIS: PRODUCT PORTFOLIO
TABLE 48.SMITH & NEPHEW: COMPANY SNAPSHOT
TABLE 49.SMITH & NEPHEW: OPERATING SEGMENTS
TABLE 50.SMITH & NEPHEW: PRODUCT PORTFOLIO
TABLE 01.U.S. INCIDENCES OF DIABETES, 2011 VS. 2030 (IN MILLION)
TABLE 02.U.S. ADVANCED WOUND CARE MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 03.INFECTION MANAGEMENT ADVANCED WOUND CARE MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 04.EXUDATE MANAGEMENT ADVANCED WOUND CARE MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 05.ACTIVE WOUND CARE MARKET ADVANCED WOUND CARE, BY TYPE, 2019–2027 ($MILLION)
TABLE 06.U.S. ADVANCED WOUND CARE FOR SKIN SUBSTITUTE, BY TYPE, 2019–2027 ($MILLION)
TABLE 07.THERAPY DEVICES ADVANCED WOUND CARE MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 08.U.S. ADVANCED WOUND CARE MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 09.U.S. ADVANCED WOUND CARE MARKET FOR CHRONIC WOUND, BY TYPE, 2019–2027 ($MILLION)
TABLE 10.PRESSURE ULCER-RELATED PRODUCTS AND MANUFACTURERS
TABLE 11.U.S. ADVANCED WOUND CARE MARKET FOR ACUTE WOUND, BY TYPE, 2019–2027 ($MILLION)
TABLE 12.U.S. ADVANCED WOUND CARE MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 13.3M: COMPANY SNAPSHOT
TABLE 14.3M: OPERATING SEGMENTS
TABLE 15.3M: PRODUCT PORTFOLIO
TABLE 16.ADYNXX: COMPANY SNAPSHOT
TABLE 17.ADYNXX: PRODUCT PORTFOLIO
TABLE 18.B BRAUN: COMPANY SNAPSHOT
TABLE 19.B BRAUN: OPERATING SEGMENTS
TABLE 20.B BRAUN: PRODUCT PORTFOLIO
TABLE 21.COLOPLAST: COMPANY SNAPSHOT
TABLE 22.COLOPLAST: OPERATING SEGMENTS
TABLE 23.COLOPLAST: PRODUCT PORTFOLIO
TABLE 24.CONVATEC: COMPANY SNAPSHOT
TABLE 25.CONVATEC: OPERATING SEGMENTS
TABLE 26.CONVATEC: PRODUCT PORTFOLIO
TABLE 27.ESSITY: COMPANY SNAPSHOT
TABLE 28.ESSITY: OPERATING SEGMENTS
TABLE 29.ESSITY: PRODUCT PORTFOLIO
TABLE 30.INTEGRA LIFESCIENCES: COMPANY SNAPSHOT
TABLE 31.INTEGRA LIFESCIENCES: OPERATING SEGMENTS
TABLE 32.INTEGRA LIFESCIENCES: PRODUCT PORTFOLIO
TABLE 33.INVESTOR: COMPANY SNAPSHOT
TABLE 34.INVESTOR: OPERATING SEGMENTS
TABLE 35.INVESTOR: PRODUCT PORTFOLIO
TABLE 36.J&J: COMPANY SNAPSHOT
TABLE 37.J&J: OPERATING SEGMENTS
TABLE 38.J&J: PRODUCT PORTFOLIO
TABLE 39.MEDLINE: COMPANY SNAPSHOT
TABLE 40.MEDLINE: OPERATING SEGMENTS
TABLE 41.MEDLINE: PRODUCT PORTFOLIO
TABLE 42.MEDTRONIC: COMPANY SNAPSHOT
TABLE 43.MEDTRONIC: OPERATING SEGMENTS
TABLE 44.MEDTRONIC: PRODUCT PORTFOLIO
TABLE 45.ORGANOGENESIS: COMPANY SNAPSHOT
TABLE 46.ORGANOGENESIS: OPERATING SEGMENTS
TABLE 47.ORGANOGENESIS: PRODUCT PORTFOLIO
TABLE 48.SMITH & NEPHEW: COMPANY SNAPSHOT
TABLE 49.SMITH & NEPHEW: OPERATING SEGMENTS
TABLE 50.SMITH & NEPHEW: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.U.S. ADVANCED WOUND CARE MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2017–2019
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2017–2019 (%)
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2017–2019
FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.HIGH THREAT OF SUBSTITUTES
FIGURE 09.LOW THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE INTENSITY OF RIVALRY
FIGURE 11.MARKET SHARE ANALYSIS
FIGURE 12.MARKET DYNAMICS
FIGURE 13.U.S. ADVANCED WOUND CARE MARKET FOR INFECTION MANAGEMENT, 2019-2027 ($MILLION)
FIGURE 14.U.S. ADVANCED WOUND CARE MARKET FOR SILVER WOUND DRESSINGS, 2019–2027 ($MILLION)
FIGURE 15.U.S. ADVANCED WOUND CARE MARKET FOR NON-SILVER DRESSINGS, 2019–2027 ($MILLION)
FIGURE 16.U.S. ADVANCED WOUND CARE MARKET FOR COLLAGEN DRESSINGS, 2019–2027 ($MILLION)
FIGURE 17.U.S. ADVANCED WOUND CARE MARKET FOR EXUDATE MANAGEMENT, 2019-2027 ($MILLION)
FIGURE 18.U.S. ADVANCED WOUND CARE MARKET FOR HYDROCOLLOID DRESSINGS, 2019–2027 ($MILLION)
FIGURE 19.U.S. ADVANCED WOUND CARE MARKET FOAM DRESSINGS, 2019–2027 ($MILLION)
FIGURE 20.U.S. ADVANCED WOUND CARE MARKET FOR ALGINATE DRESSINGS, 2019–2027 ($MILLION)
FIGURE 21.U.S. ADVANCED WOUND CARE MARKET FOR HYDROGEL DRESSINGS, 2019–2027 ($MILLION)
FIGURE 22.U.S. ADVANCED WOUND CARE MARKET FOR ACTIVE WOUND CARE, 2019-2027 ($MILLION)
FIGURE 23.U.S. ADVANCED WOUND CARE MARKET FOR XENOGRAFT, 2019–2027 ($MILLION)
FIGURE 24.U.S. ADVANCED WOUND CARE MARKET FOR ALLOGRAFTS, 2019–2027 ($MILLION)
FIGURE 25.U.S. ADVANCED WOUND CARE MARKET FOR CELL-BASED BIOENGINEERING, 2019–2027 ($MILLION)
FIGURE 26.GROWTH FACTORS ADVANCED WOUND CARE MARKET, 2019–2027 ($MILLION)
FIGURE 27.U.S. ADVANCED WOUND CARE MARKET FOR NEGATIVE PRESSURE WOUND THERAPY, 2019–2027 ($MILLION)
FIGURE 28.U.S. ADVANCED WOUND CARE MARKET FOR OXYGEN AND HYPERBARIC OXYGEN EQUIPMENT, 2019–2027 ($MILLION)
FIGURE 29.U.S. ADVANCED WOUND CARE MARKET FOR ELECTROMAGNETIC THERAPY DEVICES, 2019–2027 ($MILLION)
FIGURE 30.OTHERS ADVANCED WOUND CARE MARKET, 2019–2027 ($MILLION)
FIGURE 31.U.S. ADVANCED WOUND CARE MARKET FOR PRESSURE ULCERS, 2019–2027 ($MILLION)
FIGURE 32.U.S. ADVANCED WOUND CARE MARKET FOR DIABETIC FOOT ULCERS, 2019–2027 ($MILLION)
FIGURE 33.U.S. ADVANCED WOUND CARE MARKET FOR VENOUS LEG ULCERS, 2019–2027 ($MILLION)
FIGURE 34.U.S. ADVANCED WOUND CARE MARKET FOR ARTERIAL ULCERS, 2019–2027 ($MILLION)
FIGURE 35.U.S. ADVANCED WOUND CARE MARKET FOR BURNS & TRAUMA, 2019–2027 ($MILLION)
FIGURE 36.U.S. ADVANCED WOUND CARE MARKET FOR SURGICAL WOUNDS, 2019–2027 ($MILLION)
FIGURE 37.U.S. ADVANCED WOUND CARE MARKET FOR HOSPITALS, 2019-2027 ($MILLION)
FIGURE 38.U.S. ADVANCED WOUND CARE MARKET FOR COMMUNITY HEALTH SERVICE CENTERS, 2020-2027 ($MILLION)
FIGURE 39.3M: NET SALES, 2017–2019 ($MILLION)
FIGURE 40.3M: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 41.3M: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 42.B BRAUN: NET SALES, 2017–2019 ($MILLION)
FIGURE 43.B BRAUN: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 44.B BRAUN: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 45.COLOPLAST: NET SALES, 2017–2019 ($MILLION)
FIGURE 46.COLOPLAST: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 47.COLOPLAST: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 48.CONVATEC: NET SALES, 2017–2019 ($MILLION)
FIGURE 49.CONVATEC: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 50.CONVATEC: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 51.ESSITY: NET SALES, 2017–2019 ($MILLION)
FIGURE 52.ESSITY: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 53.ESSITY: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 54.INTEGRA LIFESCIENCES: NET SALES, 2017–2019 ($MILLION)
FIGURE 55.INTEGRA LIFESCIENCES: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 56.INTEGRA LIFESCIENCES: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 57.INVESTOR: NET SALES, 2017–2019 ($MILLION)
FIGURE 58.INVESTOR: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 59.INVESTOR: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 60.J&J: NET SALES, 2017–2019 ($MILLION)
FIGURE 61.J&J: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 62.J&J: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 63.MEDTRONIC: NET SALES, 2017–2019 ($MILLION)
FIGURE 64.MEDTRONIC: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 65.MEDTRONIC: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 66.ORGANOGENESIS: NET SALES, 2017–2019 ($MILLION)
FIGURE 67.ORGANOGENESIS: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 68.SMITH & NEPHEW: NET SALES, 2017–2019 ($MILLION)
FIGURE 69.SMITH & NEPHEW: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 70.SMITH & NEPHEW: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 01.U.S. ADVANCED WOUND CARE MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2017–2019
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2017–2019 (%)
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2017–2019
FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.HIGH THREAT OF SUBSTITUTES
FIGURE 09.LOW THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE INTENSITY OF RIVALRY
FIGURE 11.MARKET SHARE ANALYSIS
FIGURE 12.MARKET DYNAMICS
FIGURE 13.U.S. ADVANCED WOUND CARE MARKET FOR INFECTION MANAGEMENT, 2019-2027 ($MILLION)
FIGURE 14.U.S. ADVANCED WOUND CARE MARKET FOR SILVER WOUND DRESSINGS, 2019–2027 ($MILLION)
FIGURE 15.U.S. ADVANCED WOUND CARE MARKET FOR NON-SILVER DRESSINGS, 2019–2027 ($MILLION)
FIGURE 16.U.S. ADVANCED WOUND CARE MARKET FOR COLLAGEN DRESSINGS, 2019–2027 ($MILLION)
FIGURE 17.U.S. ADVANCED WOUND CARE MARKET FOR EXUDATE MANAGEMENT, 2019-2027 ($MILLION)
FIGURE 18.U.S. ADVANCED WOUND CARE MARKET FOR HYDROCOLLOID DRESSINGS, 2019–2027 ($MILLION)
FIGURE 19.U.S. ADVANCED WOUND CARE MARKET FOAM DRESSINGS, 2019–2027 ($MILLION)
FIGURE 20.U.S. ADVANCED WOUND CARE MARKET FOR ALGINATE DRESSINGS, 2019–2027 ($MILLION)
FIGURE 21.U.S. ADVANCED WOUND CARE MARKET FOR HYDROGEL DRESSINGS, 2019–2027 ($MILLION)
FIGURE 22.U.S. ADVANCED WOUND CARE MARKET FOR ACTIVE WOUND CARE, 2019-2027 ($MILLION)
FIGURE 23.U.S. ADVANCED WOUND CARE MARKET FOR XENOGRAFT, 2019–2027 ($MILLION)
FIGURE 24.U.S. ADVANCED WOUND CARE MARKET FOR ALLOGRAFTS, 2019–2027 ($MILLION)
FIGURE 25.U.S. ADVANCED WOUND CARE MARKET FOR CELL-BASED BIOENGINEERING, 2019–2027 ($MILLION)
FIGURE 26.GROWTH FACTORS ADVANCED WOUND CARE MARKET, 2019–2027 ($MILLION)
FIGURE 27.U.S. ADVANCED WOUND CARE MARKET FOR NEGATIVE PRESSURE WOUND THERAPY, 2019–2027 ($MILLION)
FIGURE 28.U.S. ADVANCED WOUND CARE MARKET FOR OXYGEN AND HYPERBARIC OXYGEN EQUIPMENT, 2019–2027 ($MILLION)
FIGURE 29.U.S. ADVANCED WOUND CARE MARKET FOR ELECTROMAGNETIC THERAPY DEVICES, 2019–2027 ($MILLION)
FIGURE 30.OTHERS ADVANCED WOUND CARE MARKET, 2019–2027 ($MILLION)
FIGURE 31.U.S. ADVANCED WOUND CARE MARKET FOR PRESSURE ULCERS, 2019–2027 ($MILLION)
FIGURE 32.U.S. ADVANCED WOUND CARE MARKET FOR DIABETIC FOOT ULCERS, 2019–2027 ($MILLION)
FIGURE 33.U.S. ADVANCED WOUND CARE MARKET FOR VENOUS LEG ULCERS, 2019–2027 ($MILLION)
FIGURE 34.U.S. ADVANCED WOUND CARE MARKET FOR ARTERIAL ULCERS, 2019–2027 ($MILLION)
FIGURE 35.U.S. ADVANCED WOUND CARE MARKET FOR BURNS & TRAUMA, 2019–2027 ($MILLION)
FIGURE 36.U.S. ADVANCED WOUND CARE MARKET FOR SURGICAL WOUNDS, 2019–2027 ($MILLION)
FIGURE 37.U.S. ADVANCED WOUND CARE MARKET FOR HOSPITALS, 2019-2027 ($MILLION)
FIGURE 38.U.S. ADVANCED WOUND CARE MARKET FOR COMMUNITY HEALTH SERVICE CENTERS, 2020-2027 ($MILLION)
FIGURE 39.3M: NET SALES, 2017–2019 ($MILLION)
FIGURE 40.3M: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 41.3M: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 42.B BRAUN: NET SALES, 2017–2019 ($MILLION)
FIGURE 43.B BRAUN: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 44.B BRAUN: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 45.COLOPLAST: NET SALES, 2017–2019 ($MILLION)
FIGURE 46.COLOPLAST: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 47.COLOPLAST: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 48.CONVATEC: NET SALES, 2017–2019 ($MILLION)
FIGURE 49.CONVATEC: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 50.CONVATEC: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 51.ESSITY: NET SALES, 2017–2019 ($MILLION)
FIGURE 52.ESSITY: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 53.ESSITY: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 54.INTEGRA LIFESCIENCES: NET SALES, 2017–2019 ($MILLION)
FIGURE 55.INTEGRA LIFESCIENCES: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 56.INTEGRA LIFESCIENCES: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 57.INVESTOR: NET SALES, 2017–2019 ($MILLION)
FIGURE 58.INVESTOR: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 59.INVESTOR: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 60.J&J: NET SALES, 2017–2019 ($MILLION)
FIGURE 61.J&J: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 62.J&J: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 63.MEDTRONIC: NET SALES, 2017–2019 ($MILLION)
FIGURE 64.MEDTRONIC: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 65.MEDTRONIC: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 66.ORGANOGENESIS: NET SALES, 2017–2019 ($MILLION)
FIGURE 67.ORGANOGENESIS: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 68.SMITH & NEPHEW: NET SALES, 2017–2019 ($MILLION)
FIGURE 69.SMITH & NEPHEW: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 70.SMITH & NEPHEW: REVENUE SHARE, BY REGION, 2019 (%)
